Expression vector of human NURR1.
Alternative name | SET-0078_2 |
---|---|
Clone info. | Expression vector of human NURR1. Expression was confirmed by Western blotting with anti-FLAG antibody. |
Comment | Derived from Sugano BC009288. PCR cloning, forward primer: ATGCCTTGTGTTCAGGCGCA; reverse primer: GCTTGGGAGGAGGTCTTAGAAAGG. |
Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
Size of vector backbone | 5.5 kb |
Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
Growth conditions | 37C, LB+Amp |
Gene/insert name | Human NURR1 cDNA |
Depositor|Developer | DNA Bank, | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL and cite Gene 200, 149-156, 1997 in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記し、指定する文献(Gene, 200, 149-156 (1997))を引用すること。 付加的使用条件: pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
Catalog # | Resource name | Shipping form | Fee |
---|---|---|---|
RDB06298 | pCMFlag_hsNR4A2 | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The pCMFlag_hsNR4A2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06298). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB06298_A3Ir.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: Sequence file: RDB06298_A3Ira.seq ![]() |
---|
>06298_06298_A3Ir_CMV-Foward_E04_13.ab1 1 AGTTCACTCC GCCCATTGAC GCAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 61 GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA 121 CTCACTATAG GGAGACCCAA GCTGAATTCA CCATGGACTA CAAGGACGAT GACGATAAGG 181 CGGCCATGCC TTGTGTTCAG GCGCAGTATG GGTCCTCGCC TCAAGGAGCC AGCCCCGCTT 241 CTCAGAGCTA CAGTTACCAC TCTTCGGGAG AATACAGCTC CGATTTCTTA ACTCCAGAGT 301 TTGTCAAGTT TAGCATGGAC CTCACCAACA CTGAAATCAC TGCCACCACT TCTCTCCCCA 361 GCTTCAGTAC CTTTATGGAC AACTACAGCA CAGGCTACGA CGTCAAGCCA CCTTGCTTGT 421 ACCAAATGCC CCTGTCCGGA CAGCAGTCCT CCATTAAGGT AGAAGACATT CAGATGCACA 481 ACTACCAGCA ACACAGCCAC CTGCCCCCCC AGTCTGAGGA GATGATGCCG CACTCCGGGT 541 CGGTTTACTA CAAGCCCTCC TCGCCCCCGA CGCCCACCAC CCCGGGCTTC CAGGTGCAGC 601 ACAGCCCCAT GTGGGACGAC CCGGGATCTC TCCACAACTT CCACCAGAAC TACGTGGCCA 661 CTACGCACAT G // |
Primer: Sequence file: RDB06298_A3Irb.seq ![]() |
>06298_06298_A3Ir_Sp6_F04_16.ab1 1 GCTGAATCCT GCTCGAGCGG CCGCTTGGGA GGAGGTCTTA GAAAGGTAAA GTGTCCAGGA 61 AAAGTTTGTC AATTATTGCT GGCGGTGGCA CCAAGTCTTC CAATTTCAGG TAGAAAATGC 121 GCTGTAGCCC CTGTGTGCAA AGGGTACGAA GTTCTGGGAG CTTCCCCAAC AGTTTGGACA 181 AATAATTGGG GCGGTTCAAC CCCCCATTGT TGAAAGTCAC GTGGTCTTTG AGACAATTTA 241 CAATCTTGTT TTGCAGTTCT TCCACTCTCT TGGGTTCCTT GAGCCCGTGT CTCTCTGTGA 301 CCATAGCCAG GGCAGCAATG CAGGAGAAGG CAGAAATGTC GATGTTCATA TTCTGCAAGT 361 TGGAGGAGAA TTCAACAATG GAATCAATCC ATTCCCCAAA GCCACGAACG CATTGCAACC 421 TGTGCAAGAC CACCCCATTG CAAAAGATGA GTTTACCCTC CACTGGGTTG GACCTGTATG 481 CTAATCGAAG GACAAACAGT TCTAAGAAAG CTGATTCAAA AAGCAGGTCT TGGTCGGCTT 541 TGGGCAGGTC TGCGAAGCCA GGGATCTTCT CTGCCCAGCC CCGGATGATC TCCATGGAGC 601 CAGTCAGGAG ATCATAGAAT TGCTGGATAT GCTGGGTGTC ATCTCCACTC ATTTGATAGT 661 CAGGGTTCGC CTGGAAC // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content